Literature DB >> 15356938

Genital herpes and human immunodeficiency virus: double trouble.

Connie Celum1, Ruth Levine, Marcia Weaver, Anna Wald.   

Abstract

The synergistic relationship between herpes simplex virus type 2 (HSV-2) and transmission of human immunodeficiency virus (HIV) can be substantial in developing countries that have high prevalences of both viral infections. Genital herpes, most frequently caused by HSV-2, has become the leading cause of genital ulcer disease worldwide. This review of recent research on genital herpes and enhanced susceptibility to, and transmission of, HIV is part of the "Advances in HIV/AIDS research series" which endeavours to form a bridge between the research into HIV and acquired immunodeficiency syndrome (AIDS) and the practice of HIV/AIDS prevention, care and support in developing countries. Research findings have shown that being seropositive for HSV-2 can increase the risk of HIV acquisition among high-risk HIV-negative people exposed to HIV and, likewise, the infectiousness of individuals co-infected with HIV-1 and HSV-2 can increase during periods of HSV-2 reactivation. These observations have led to the initiation of several intervention trials and could ultimately lead to the setting of new priorities in public health and clinical practice. WHO has recently issued new guidelines for the syndromic management of genital ulcer disease that include antiviral treatment for lesions consistent with genital herpes. The United States Centers for Disease Control and Prevention issued updated Sexually Transmitted Diseases Treatment Guidelines in 2002 that recommended the use of type-specific serological tests for diagnosing HSV-2. Recently launched proof-of-concept, HSV-2 intervention trials in several countries will help to determine the proportion of new HIV infections that could be prevented by suppression of HSV-2, and the findings from these studies will inform those involved in setting prevention and treatment priorities and strategies in developing countries.

Entities:  

Mesh:

Year:  2004        PMID: 15356938      PMCID: PMC2622854     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  55 in total

Review 1.  Rapid tests for sexually transmitted infections (STIs): the way forward.

Authors:  R W Peeling; K K Holmes; D Mabey; A Ronald
Journal:  Sex Transm Infect       Date:  2006-12-06       Impact factor: 3.519

2.  Sensitivity and specificity of herpes simplex virus-2 serological assays among HIV-infected and uninfected urban Ugandans.

Authors:  J Lingappa; E Nakku-Joloba; A Magaret; D Friedrich; J Dragavon; F Kambugu; M Joloba; C Whalen; R Coombs; C Celum; R Ashley Morrow
Journal:  Int J STD AIDS       Date:  2010-09       Impact factor: 1.359

Review 3.  Genital herpes and its management.

Authors:  P Sen; S E Barton
Journal:  BMJ       Date:  2007-05-19

Review 4.  Optimizing siRNA delivery to the genital mucosa.

Authors:  Joseph A Katakowski; Deborah Palliser
Journal:  Discov Med       Date:  2011-02       Impact factor: 2.970

5.  Genital herpes in Canada: Deciphering the hidden epidemic.

Authors:  Mubeen Aslam; Rhonda Y Kropp; Gayatri Jayaraman; Katherine Dinner; Thomas Wong; Marc Steben
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

6.  PPARgamma and LXR signaling inhibit dendritic cell-mediated HIV-1 capture and trans-infection.

Authors:  Timothy M Hanley; Wendy Blay Puryear; Suryaram Gummuluru; Gregory A Viglianti
Journal:  PLoS Pathog       Date:  2010-07-01       Impact factor: 6.823

7.  Seroprevalence and factors associated with herpes simplex virus type 2 among HIV-negative high-risk men who have sex with men from Rio de Janeiro, Brazil: a cross-sectional study.

Authors:  Junia Rodrigues; Beatriz Grinsztejn; Francisco I Bastos; Luciane Velasque; Paula M Luz; Claudia T V de Souza; Ingebourg Georg; Jose H Pilotto; Valdilea G Veloso
Journal:  BMC Infect Dis       Date:  2009-04-01       Impact factor: 3.090

8.  Population-level effect of HSV-2 therapy on the incidence of HIV in sub-Saharan Africa.

Authors:  R G White; E E Freeman; K K Orroth; R Bakker; H A Weiss; N O'Farrell; A Buvé; R J Hayes; J R Glynn
Journal:  Sex Transm Infect       Date:  2008-10       Impact factor: 3.519

9.  Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa.

Authors:  Esther E Freeman; Richard G White; Roel Bakker; Kate K Orroth; Helen A Weiss; Anne Buvé; Richard J Hayes; Judith R Glynn
Journal:  Vaccine       Date:  2008-12-09       Impact factor: 3.641

10.  Relatively low HIV infection rates in rural Uganda, but with high potential for a rise: a cohort study in Kayunga District, Uganda.

Authors:  David Guwatudde; Fred Wabwire-Mangen; Leigh Anne Eller; Michael Eller; Francine McCutchan; Hannah Kibuuka; Monica Millard; Nelson Sewankambo; David Serwadda; Nelson Michael; Merlin Robb
Journal:  PLoS One       Date:  2009-01-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.